Views & Analysis ‘No going back’ for clinical trials after COVID Trial sites have adapted swiftly to the restrictions of COVID-19, and patients have seen many knock-on benefits as a result.
News PBM reform dropped in Congress' funding package Proposed reforms to the regulations for PBMs were dropped from the US Congress' end-of-year bill to provide funding to the federal government.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
